

SCREENED (SIGNED INFORMED CONSENT FORM) N=173
SCREEN FAILURES N=35
RANDOMIZED N=138
RANDOMIZED, BUT NOT TREATED N=5 (4%)
• WITHDREW CONSENT PRIOR TO TREATMENT: N=1
• INREASING CREATININE AND TOTAL BILIRUBIN: N=1
• WITHDREW FROM STUDY: N=2
• LOST TO FOLLOW-UP: N=1
TREATED N=133 (96%)
DISCONTINUED TREATMENT N=133 (100%)
• ADVERSE EVENT: N=9 (7%)
• DEATH: N=11 (8%)
• PROGRESSIVE DISEASE: N=32 (24%)
• ALTERNATIVE MDS/CMML THERAPY: N=3 (2%)
• PATIENT DECISION TO STOP TREATMENT: N=6 (5%)
• BONE MARROW/STEM CELL TRANSPLANT: N=27 (20%)
• LOST TO FOLLOW-UP: N=0
• OTHER: N=45 (34%)
WITHDRAWN FROM STUDY N=137 (99%)
• DEATH: N=58 (42%)
• COMPLETE CONSENT WITHDRAWAL: N=8 (6%)
• LOST TO FOLLOW-UP: N=1 (<1%)
• STUDY TERMINATED BY SPONSOR: N=42 (30%)
• ROLLOVER TO ASTX727-06: N=28 (20%)
CONTINUING IN STUDY N=1 (<1%)
• ON STUDY TREATMENT: N=0
• SURVIVAL FOLLOW-UP: N=1 (<1%)

FIG. 1



DAY 1 DECITABINE 20 mg/m2
DAY 5 DECITABINE 20 mg/m2
DAY 1 ORAL DECITABINE AND CEDAZURIDE
DAY 2 ORAL DECITABINE AND CEDAZURIDE
DAY 5 ORAL DECITABINE AND CEDAZURIDE
MEAN PLASMA DECITABINE CONC., ng/mL
200
150
100
50
0
0 1 2 3 4 5 6 7 8
NOMINAL TIME, H

FIG. 2A



DAY 1 DECITABINE 20 mg/m2
DAY 5 DECITABINE 20 mg/m2
DAY 1 ORAL DECITABINE AND CEDAZURIDE
DAY 2 ORAL DECITABINE AND CEDAZURIDE
DAY 5 ORAL DECITABINE AND CEDAZURIDE
MEAN PLASMA DECITABINE CONC., ng/mL
1000
100
10
1
0.1
0.01
LLOO
0 1 2 3 4 5 6 7 8
NOMINAL TIME, H

FIG. 2B



1.0
0.8
0.6
0.4
0.2
SURVIVAL PROBABILITY
SEQUENCE A
SEQUENCE B
TOTAL
SEQUENCE A 66 61 54 47 43 40 34 29 28 13 6 1 0
SEQUENCE B 67 64 60 54 50 45 45 44 42 25 9 3 0
TOTAL 133 125 114 101 93 85 79 73 70 38 15 4 0
0 100 200 300 400 500 600 700 800 900 1000 1100 1200
LEUKEMIA-FREE SURVIVAL (DAYS)

FIG. 3



1.0
0.8
0.6
0.4
0.2
SURVIVAL PROBABILITY
SEQUENCE A
SEQUENCE B
TOTAL
SEQUENCE A 66 64 58 53 49 46 40 33 23 11 2 0
SEQUENCE B 67 65 61 57 53 48 46 46 39 11 5 2 0
TOTAL 133 129 119 110 102 94 86 79 62 22 7 2 0
0 100 200 300 400 500 600 700 800 900 1000 1100 1200
OVERALL SURVIVAL (DAYS)

FIG. 4



1.0
0.8
0.6
0.4
0.2
SURVIVAL PROBABILITY
CMML
INT-1/LR
CMML 16 16 14 12 12 11 11 9 8 3 1 0
INT-1/LR 69 66 63 59 58 56 53 50 49 30 12 4 0
0 100 200 300 400 500 600 700 800 900 1000 1100 1200
LEUKEMIA-FREE SURVIVAL (DAYS)

FIG. 5



1.0
0.8
0.6
0.4
0.2
SURVIVAL PROBABILITY
CMML
INT-1/LR
CMML 16 16 15 14 13 13 13 10 9 4 1 0
INT-1/LR 69 67 64 60 59 57 53 52 50 30 12 4 0
0 100 200 300 400 500 600 700 800 900 1000 1100 1200
OVERALL SURVIVAL (DAYS)

FIG. 6



1.0
0.8
0.6
0.4
0.2
0.0
SURVIVAL PROBABILITY
+ CENSORED
TP53-WT
TP53mut
TP53-WT 31 69 52 10 0
TP53mut 44 32 24 5 0
0 10 20 30 40
ANALYSIS VALUE

FIG. 7



1.0
0.8
0.6
0.4
0.2
0.0
SURVIVAL PROBABILITY
+ CENSORED
MUTATION-BIALLELIC
MUTATION-MONOALLELIC
BIALLELIC 14 7 4 1
MONOALLELIC 30 25 20 4
0 10 20 30
ANALYSIS VALUE

FIG. 8